Single conservative and nonconservative amino acid substitutions were introduced into the gp45 external envelope protein (SU) of human T-cell leukemia virus type I (HTLV-I). The mutated amino acids were those identified as being conserved in HTLV-I, HTLV-II, and simian T-cell leukemia virus type I (but not in bovine leukemia virus). The mutated envelopes were tested for intracellular maturation and for function. Mutants with three major phenotypes could be defined: (i) 9 mutants with a wild-type phenotype, which included most of the conservative amino acid changes (five of seven) distributed throughout the SU protein; (ii) 8 mutants with affected intracellular maturation, 6 of which define a region in the central part of the SU protein essential for correct folding of the protein; and (iii) 13 mutants with normal intracellular maturation but impaired syncytium formation. These mutations likely affect the receptor binding step or postbinding events required for fusion. Five of these mutations are located between amino acids 75 and 101 of the SU protein, in the amino-terminal third of the molecule. The other mutations involve positions 170, 181, 195, 197, 208, 233, and 286, suggesting that two other domains, one central and one carboxy terminal, are involved in HTLV-I envelope functions.
Human T-cell leukemia virus type I (HTLV-I) is implicated in two different diseases: adult T-cell leukemia, a severe type of T-lymphocyte neoplasia, and a neuropathy, the tropical spastic paraparesis also called HTLV-I-associated myelopathy. HTLV-I is endemic in several parts of the world, including Japan (3), Africa (38) , and the Caribbean region (3) . One to four percent of infected individuals may develop one or the other disease in their lifetimes (25) . The development of a vaccine against HTLV-I will probably be centered on the use of the external envelope glycoprotein of the virus, which exhibits a high degree of conservation among different strains (6, 7, 12, 16, 17, 24, 28, 39, 47) .
The HTLV-I envelope glycoprotein, like the envelope glycoprotein of other retroviruses (for reviews, see references 15 and 49) , is synthesized as a precursor product of 488 amino acids (13, 23) . This glycoprotein is then cleaved by a cellular protease into two mature products, a surface protein (SU) of 313 amino acids and a transmembrane protein (TM) which allows anchoring of the SU-TM complex at the cell surface. Most sera from HTLV-I-infected people contain antibodies directed to peptides from the carboxy-terminal half of the envelope SU protein, whereas only a small percentage of sera react with peptides from the amino-terminal half of the SU (4, 14, 20, 30) . In the TM protein, only the intracytoplasmic domain contains reactive linear epitopes (14) . All sera from infected individuals, however, contain neutralizing antibodies. Linear peptide targets for neutralizing antibodies are found in two regions of the HTLV-I SU protein; the first region is localized around amino acids 187 to 199 of the SU protein (1, 21, 46) , and the second target region, characterized more recently by using goat sera, is in the amino-terminal part of the SU, between amino acids 88 and 98 (29) . It is not known whether neutralizing antibodies in human HTLV-I carriers recognize predominantly linear or conformational epitopes.
In the retrovirus life cycle, the envelope glycoproteins are implicated in viral entry into the target cell (reviewed in references 9, 15, and 49), including binding to a specific receptor, followed by postbinding events leading to fusion of the viral envelope with the plasma membrane of the target cell. Regions of the retroviral envelope proteins important for their function are now well documented in murine (2, 26, 27, 43) and avian (9) retroviruses. In human immunodeficiency virus, these regions are being defined with increasing precision (10, 18, 22, 34, 44, 50) . However, there is little published information on the HTLV-I envelope proteins. Our previous findings suggested that a region of the SU protein, between amino acids 195 and 205, is important for function (33) . The present study further defines, through the use of single amino acid substitutions, new regions important for envelope function.
MATERIALS AND METHODS
Cell lines. COS-1 cells (11) and HeLa cells were obtained from the American Type Culture Collection and grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. The sarcoma virus-transformed XC cells (45) used as indicator cells in the syncytium formation assay were a generous gift from S. Gisaelbrecht (Hopital Cochin, Paris, France). They were grown in minimum essential medium containing 10% fetal calf serum. All cell lines were maintained at 37°C in a 5% CO2 atmosphere.
HTLV-I envelope expressor plasmid. The HTLV-I envelope expressor plasmid is the HTE-1 expressor previously described (8 Detection of the envelope proteins by radioimmunoprecipitation. Transfected COS-1 cells were labeled, and the envelope products were immunoprecipitated as previously described (33) , using tropical spastic paraparesis patient serum (a gift from Y. Coste, CRTS, Montpellier, France), both from the transfected cell lysates (to assess envelope expression and maturation) and from the transfected cell supernatants (to assess SU-to-TM association). The envelope proteins were visualized by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis under reducing conditions followed by autoradiography. Cleavage of the gp6l precursor into the mature SU gp45 and TM gp20 products in mutant envelope was compared with wild-type precursor cleavage by scanning the exposed films with a Chromoscan III apparatus (Joyce-Loebl Ltd.). The relative percentage of cleavage was calculated as (counts for TM gp2O/counts for gp6l precursor for the mutated protein)/ (counts for TM gp2O/counts for gp6l precursor for the wildtype protein) x 100. In Table 1 , this percentage is given as the mean percentage obtained from two to three independent experiments.
Syncytium formation assay. The syncytium formation assay was previously described (33) 
RESULTS
Choice of point mutations and nomenclature of amino acid substitution mutants. To define the HTLV-I SU glycoprotein regions important for envelope functionality, 23 different amino acid positions were changed by site-directed mutagenesis in the HTLV-I env gene. These residues (indicated in Table 1 ) were selected on the basis of two main criteria. First, they were all conserved among the then published sequences of HTLV-I isolates (6, 7, 12, 16, 17, 24, 28, 39, 47) . Second, most of them were also conserved among HTLV-I, HTLV-II (40, 41) , and simian T-cell leukemia virus type I (STLV-I) (48), which share a common cell surface receptor, but not in bovine leukemia virus (BLV) (36, 37) , which uses a different cell surface receptor on human cells (42) . All 23 selected residues were changed nonconservatively, since this was more likely to affect envelope functions. For seven positions in regions in the SU defined as important for function (see below), a second change, consisting of a conservative substitution, was also performed. The mutated constructions were named HTE-X (Table 1) , X referring to the position of the mutated amino acid (where Met, the initiation codon of the envelope, is residue 1). When a conservative mutation was made, the construct was named HTE-Xbis. The corresponding mutated proteins were named amino acid 1X-amino acid 2 (for instance, Ser-58-*Leu), where amino acid I is the original wild-type amino acid and amino acid 2 is the substituted amino acid ( Table 1 ).
The mutated constructions were transfected into COS-1 cells and compared with the plasmid expressing wild-type envelope proteins (HTE-1) with regard to envelope glycoprotein expression, processing, SU-to-TM association, and syncytium formation.
Intracellular maturation of the mutated envelope glycoproteins. To examine the effects of the mutations on envelope synthesis and intracellular maturation, transfected cells were metabolically labeled and analyzed by immunoprecipitation ( Fig. 1 and Table 1 ). For each mutated protein, gp6l precursor cleavage into mature SU gp45 and TM gp2O was compared with wild-type precursor cleavage, and the relative percentage of cleavage was calculated. Figure 1 shows that none of the mutations had a significant effect on envelope product stability, since comparable amounts of the envelope precursor gp6l were detected in all cases (compare the amounts of wild-type and mutated envelope precursor products in the various gels). Most of the mutated proteins exhibited a mobility in SDSpolyacrylamide gels comparable to that of the wild-type precursor except for Asp-197--Wal (Fig. 1, lane 37) and Thr-212--Ile (Fig. 1, lane 41) . The slightly faster mobility consistently shown by these two mutated proteins might reflect disruption of precursor protein glycosylation. In particular, the mutation at position 212 (Thr-212-Ile) might affect 0 glycosylation of the precursor.
Among the 30 mutations, 22 had little or no effect on the gp6l precursor cleavage into the SU and TM products, whereas 8 mutations significantly affected precursor cleavage compared with that of the wild-type envelope (Table 1 ; less than 20% cleavage). These eight mutated proteins, shown in The envelope products were also immunoprecipitated from the transfected cell supernatants to examine a possible disruption of the SU-to-TM association. Previous work from our group had shown that the two proteins are not covalently linked (31) . One mutation, Tyr-170--Ser (lane 28), resulted in secretion of large amounts of SU protein into the supernatant (left part of the lane). The quantity of secreted SU in this mutant was comparable to that obtained with a truncated envelope having a nonsense codon proximal to the anchorage domain of the TM protein ( Fig. 1 ; compare lane 27 with lane 28) (32) . None of the other mutations disrupted the association between SU and TM proteins, since no product was detected in the supernatant.
Biological activity of the mutated envelopes. The effects of the mutations on HTLV-I envelope function were examined by scoring syncytium formation. In each case, two different indicator cell lines (XC cells and HeLa cells) were used, with identical results. As shown in Table 1 , nine mutations did not affect syncytium formation. These were Asn-95->Asp, Ser-105->Leu, Ser-105->Thr, Ser-181->Thr, Ser-194--Phe, Ser-194->Thr, Asn-195-*Asp, Ser-203-->Phe, and Ser-220-Ile. Note that most of these mutations produced a conservative amino acid substitution. One of these mutated proteins (Ser-194->Phe) exhibited normal syncytium formation despite a marked reduction of the precursor cleavage (34% of the value for the wild-type envelope). This indicates that at least in some cases, only a small r'Numbers of syncytia per well were scored as described in Materials and Methods.
amount of cleaved products is needed to elicit normal syncytium formation. Twenty-one mutants gave no syncytia or exhibited abnormal syncytium formation. These included the eight mutations which affected precursor cleavage as described above. The remaining 13 mutations which affected syncytium formation exhibited normal maturation or slightly affected precursor cleavage. serine residue was substituted, since this amino acid, despite its hydrophilic nature, is not usually important for the stability of protein secondary or tertiary structure. Such mutations are more likely to detect late functional steps rather than intracellular maturation.
The mutants could be divided into three different categories. The first includes mutations with normal or near normal maturation and syncytium formation. These are essentially conservative mutations (five of our seven conservative changes). Conversely, nonconservative amino acid substitutions led in most (19 of 23) cases to a nonfunctional protein. This finding suggests that only conservative mutations are tolerated by the SU in the positions conserved between HTLV-I, HTLV-II, and STLV-I, corroborating our previous work (33) .
The second group consists of mutations which affect intracellular maturation (Fig. 2) . Most unaffected (51% of the wild-type value), meaning that the global conformation of the mutated protein is probably unchanged. This Tyr is conserved in BLV (36, 37) , in which it might play a similar role in the SU-to-TM association.
The third category of mutant displays normal intracellular maturation but altered syncytium formation (Fig. 2) (1) .
Whether these defined amino-terminal, central, and carboxy-terminal domains function independently or are part of the same conformational structure is also unclear; in particular, we cannot distinguish between receptor binding and postbinding events. However, these studies further elucidate structure-function relationships in the HTLV-I envelope and will aid in the design of an effective vaccine.
